Novo Nordisk partners with Anthropic to use Claude for drug discovery and R&D
Novo will initially pilot Claude Science on specific workflows and collaborate with Anthropic to develop targeted solutions for scientific challenges; the partnership aims to increase R&D productivity.
In this brief: 2 sections 1 min read
Initial focus: Novo will test Anthropic models and Claude Science on research and development workflows identified by Novo scientists.
Joint work: companies will jointly address scientific problems and develop targeted AI-enabled solutions for specific workflows.
Agentic engineering: collaboration includes applying Anthropic’s agentic software engineering capabilities to scale AI usage in Novo’s software development.
Novo view: the partnership aims to accelerate discovery and compress time from research to marketed products.
Anthropic view: CEO Dario Amodei framed access to frontier models as a way to shorten research timelines and improve outcomes.
Deployment: initial pilots will determine how Claude models are applied across Novo’s R&D.